ASH 2022 | Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses results from a retrospective study of venetoclax-based regimens for patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with excess blasts-2. Dr Zucenka discusses survival outcomes and possible markers of response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
